30 October 2024 in Molecular Cancer Research
Approximately 70% of oropharyngeal squamous carcinomas (OPSCC) are associated with human papillomavirus (HPV). Although patients with HPV-positive (HPV+) tumors generally have better outcomes than those with HPV-negative tumors, a subset of HPV+ positive patients do have poor outcomes. Our previous work suggested that tumors with integrated virus exhibit significantly greater genome-wide genomic instability than those with only episomal viral genomes, and patients with HPV+ OPSCC with episomal viral genomes had better outcomes. To explore the causal relation between viral integration and genomic instability, we have examined the time course of viral integration and genetic instability in tonsillar keratinocytes transformed with HPV16. HPV-infected human tonsil keratinocyte cell lines were continuously passaged, and every fifth passage, some cells were retained for genomic analysis. Whole-genome sequencing and optical genomic mapping confirmed that virus integrated in five of six cell lines while remaining episomal in the sixth. In all lines, genome instability occurred during early passages but essentially ceased following viral integration; however, it continued to occur in later passages in the episomal line. To test tumorigenicity of the cell lines, cells were injected subcutaneously into the flanks of nude mice. A cell line with the integrated virus induced tumors following injection in the nude mouse whereas that with the episomal virus did not. Implications: Genomic instability in HPV OPSCC tumors is not the result of viral integration but likely promotes integration. Moreover, transformants with episomal virus seem to be less tumorigenic than those with integrated virus.
8 January 2026 in OTO Open
Objective: Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) have shown remarkable results in glycemic control for patients with type 2 diabetes (T2DM). While no association has been made, there is a concern for thyroid cancer (TC) from GLP‐1RA. We aimed to study the 5‐year risk of TC in T2DM patients taking GLP‐1RA. Study Design: Retrospective cohort. Setting: TriNetX database. Methods: TriNetX was queried to identify T2DM patients between 2017 and 2019. The 5‐year risk of TC in patients using GLP‐1RA was compared to patients taking sodium‐glucose cotransporter 2 inhibitors (SGLT‐2I), metformin, and dipeptidyl peptidase 4 inhibitors (DPP‐4I) after propensity score matching by demographics and comorbidities. Results: On analysis of T2DM patients taking GLP‐1RA compared to SGLT‐2I, 7736 patients were in each cohort after matching. The 5‐year rate of TC in patients taking GLP‐1RA was 0.30% compared to 0.48% in those taking SGLT‐2I (RR 0.62 (95% CI 0.37‐1.05); P = .07). Analysis of GLP‐1RA versus metformin yielded 5158 patients in each cohort. Patients taking GLP‐1RA had similar rates of TC compared to those taking metformin (0.25% vs 0.39%; RR 0.65 (95% CI 0.32‐1.31); P = .22). A comparison of GLP‐1RA versus DPP‐4I yielded 12,570 patients in each cohort. The rate of TC was not increased in those taking GLP‐1RA compared to those taking DPP‐4I (0.33% vs 0.37%; RR 0.91 (0.60‐1.39); P = .67). Conclusion: T2DM patients taking GLP‐1RA may not have an increased 5‐year risk of TC compared to those taking metformin, SGLT‐2I, or DPP‐4I. Conclusions of long‐term use are limited as most GLP‐1RA were approved within the last decade.